Results 61 to 70 of about 15,218 (253)
F1000Research, 2013 We estimated lifetime prevalence of psychedelic use (lysergic acid diethylamide (LSD), psilocybin (magic mushrooms), mescaline, and peyote) by age category using data from a 2010 US population survey of 57,873 individuals aged 12 years and older.
Teri S Krebs, Pål-Ørjan Johansen
doaj +1 more source
Biomolecules, 2020 Several pharmacological properties are attributed to ergot alkaloids as a result of their antibacterial, antiproliferative, and antioxidant effects.
Iara Baldim +12 more
doaj +1 more source
The bridge between classical and ‘synthetic’/chemical psychoses: towards a clinical, psychopathological and therapeutic perspective [PDF]
, 2019 © 2019 Orsolini, Chiappini, Papanti, De Berardis, Corkery and Schifano. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY).
Chiappini, Stephania +5 more
core +2 more sources
Safety pharmacology of acute mescaline administration in healthy participants
British Journal of Clinical Pharmacology, EarlyView.Aims Psychedelics, including mescaline, may serve as novel treatments for depression and anxiety. However, data is scarce on the safety of mescaline. Methods The present pooled analysis included two double‐blind, randomized, placebo‐controlled studies with a total of 48 participants and 96 mescaline administrations. Single oral‐dose administrations (n =
Aaron Klaiber +4 more
wiley +1 more source
Trials, 2021 Background Regular ingestion of sub-hallucinogenic doses of psychedelics, referred to as “microdosing”, has gained increasing popularity and attention in the press and in online forums, with reported benefits across multiple cognitive and emotional ...
Robin J. Murphy +10 more
doaj +1 more source
Reaction of N,N-Dimethyltryptamine with Dichloromethane Under Common Experimental Conditions. [PDF]
, 2018 A large number of clinically used drugs and experimental pharmaceuticals possess the N,N-dimethyltryptamine (DMT) structural core. Previous reports have described the reaction of this motif with dichloromethane (DCM), a common laboratory solvent used ...
Dunlap, Lee E, Olson, David E
core +3 more sources
Preclinical models for evaluating psychedelics in the treatment of major depressive disorder
British Journal of Pharmacology, EarlyView.Psychedelic drugs have seen a resurgence in interest as a next generation of psychiatric medicines with potential as rapid‐acting antidepressants (RAADs). Despite promising early clinical trials, the mechanisms which underlie the effects of psychedelics are poorly understood.
Laith Alexander +5 more
wiley +1 more source
Psychedelics as a Treatment for Alzheimer’s Disease Dementia
Frontiers in Synaptic Neuroscience, 2020 Currently, there are no disease-modifying treatments for Alzheimer’s disease (AD) or any other dementia subtype. The renaissance in psychedelic research in recent years, in particular studies involving psilocybin and lysergic acid diethylamide (LSD ...
Simon Andrew Vann Jones +1 more
doaj +1 more source
Classical and non-classical psychedelic drugs induce common network changes in human cortex
NeuroImage, 2023 The neurobiology of the psychedelic experience is not fully understood. Identifying common brain network changes induced by both classical (i.e., acting at the 5-HT2 receptor) and non-classical psychedelics would provide mechanistic insight into state ...
Rui Dai +10 more
doaj +1 more source
British Journal of Pharmacology, EarlyView.Abstract The past decade has seen a huge increase in clinical research with psychedelic drugs and 3,4‐methylenedioxymethamphetamine (MDMA), which have revealed great potential for treating mental health conditions. Given this progress in research, as well as the current unmet clinical need of millions of patients, in 2023, the Australian Therapeutic ...
David J Nutt +3 more
wiley +1 more source